{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:24:42Z","timestamp":1782854682821,"version":"3.54.5"},"reference-count":27,"publisher":"Royal Society of Chemistry (RSC)","issue":"12","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":68,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100011821","name":"Ministry of Education \u2013 Kingdom of Saudi Arabi","doi-asserted-by":"publisher","award":["IFKSURG-2-1066"],"award-info":[{"award-number":["IFKSURG-2-1066"]}],"id":[{"id":"10.13039\/501100011821","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rsc.org"],"crossmark-restriction":true},"short-container-title":["RSC Adv."],"abstract":"<jats:p>Duvelisib (DUV) is a new oral phosphoinositide-3-kinase (PI3K)-\u03b4 and PI3K-\u03b3 inhibitor.<\/jats:p>","DOI":"10.1039\/d3ra00310h","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T05:44:39Z","timestamp":1678427079000},"page":"7929-7938","update-policy":"https:\/\/doi.org\/10.1039\/rsc_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Development and validation of an UPLC-ESI-MS\/MS method for quantification of duvelisib in plasma: application to pharmacokinetic study in rats"],"prefix":"10.1039","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3821-623X","authenticated-orcid":false,"given":"Ibrahim A.","family":"Darwish","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourah Z.","family":"Alzoman","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliyah","family":"Almomen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8711-3873","authenticated-orcid":false,"given":"Abdulrahman A.","family":"Almehizia","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1147-4960","authenticated-orcid":false,"given":"Mohamed W.","family":"Attwa","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany W.","family":"Darwish","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Y.","family":"Sayed","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"292","published-online":{"date-parts":[[2023]]},"reference":[{"key":"D3RA00310H\/cit1\/1","volume-title":"Chronic lymphocytic leukemia, Ontario","author":"Canadian Cancer Society","year":"2019","unstructured":"Canadian Cancer Society , Chronic lymphocytic leukemia, Ontario , 2019 , Available from: https:\/\/www.cancer.ca\/en\/cancer-information\/cancer-type\/leukemia-chronic-lymphocytic-cll\/chronic-lymphocytic-leukemia\/?region=on , accessed on November 20, 2022"},{"key":"D3RA00310H\/cit2\/1","volume-title":"Key statistics for chronic lymphocytic leukemia, Washington","author":"The American Chemical Society","year":"2019","unstructured":"The American Chemical Society , Key statistics for chronic lymphocytic leukemia, Washington , 2019 , available from: https:\/\/www.cancer.org\/cancer\/chronic-lymphocytic-leukemia\/about\/key-statistics.html , accessed on November 20, 2022"},{"key":"D3RA00310H\/cit3\/1","volume-title":"Chronic lymphocytic leukemia treatment protocols, New York","author":"Kotiah","year":"2019","unstructured":"S. D.Kotiah , Chronic lymphocytic leukemia treatment protocols, New York , 2019 , available from: https:\/\/emedicine.medscape.com\/article\/2005390-overview , accessed on November 20, 2022"},{"issue":"3","key":"D3RA00310H\/cit4\/1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/107327481201900303","volume":"19","author":"Bello","year":"2012","journal-title":"Cancer Control"},{"issue":"6","key":"D3RA00310H\/cit5\/1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.20020805","volume":"196","author":"Clayton","year":"2002","journal-title":"J. Exp. Med."},{"issue":"4","key":"D3RA00310H\/cit6\/1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cellsig.2010.10.002","volume":"23","author":"Fung-Leung","year":"2011","journal-title":"Cell. Signalling"},{"issue":"21","key":"D3RA00310H\/cit7\/1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood.V124.21.328.328","volume":"124","author":"Peluso","year":"2014","journal-title":"Blood"},{"issue":"13","key":"D3RA00310H\/cit8\/1","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"5583","key":"D3RA00310H\/cit9\/1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"issue":"5","key":"D3RA00310H\/cit10\/1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"8","key":"D3RA00310H\/cit11\/1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0200725","volume":"13","author":"Faia","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"D3RA00310H\/cit12\/1","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","volume":"21","author":"Qingshan","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"D3RA00310H\/cit13\/1","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2015.105","volume":"29","author":"Balakrishnan","year":"2015","journal-title":"Leukemia"},{"key":"D3RA00310H\/cit14\/1","volume-title":"Duvelisib (Copiktra, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Maryland","author":"U.S. Food & Drug Administration (FDA)","year":"2018","unstructured":"U.S. Food & Drug Administration (FDA) , Duvelisib (Copiktra, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Maryland , 2018 , available from: https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm621503.htm , accessed on November 20, 2022"},{"key":"D3RA00310H\/cit15\/1","volume-title":"Duvelisib granted priority review for R\/R CLL\/SLL and FL","author":"Leah","year":"2018","unstructured":"L.Leah , Duvelisib granted priority review for R\/R CLL\/SLL and FL , Cancer Network , 2018 , available from: https:\/\/www.cancernetwork.com\/view\/duvelisib-granted-priority-review-rr-cllsll-and-fl , accessed on November 20, 2022"},{"issue":"4","key":"D3RA00310H\/cit16\/1","doi-asserted-by":"crossref","first-page":"e5015","DOI":"10.1002\/bmc.5015","volume":"35","author":"Siddesh","year":"2020","journal-title":"Biomed. Chromatogr."},{"issue":"5","key":"D3RA00310H\/cit17\/1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13318-017-0402-5","volume":"42","author":"Nigade","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"D3RA00310H\/cit18\/1","doi-asserted-by":"crossref","first-page":"113355","DOI":"10.1016\/j.jpba.2020.113355","volume":"187","author":"Shao","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"D3RA00310H\/cit19\/1","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.2147\/DDDT.S318714","volume":"15","author":"Sayed","year":"2021","journal-title":"Drug Des., Dev. Ther."},{"key":"D3RA00310H\/cit20\/1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jchromb.2011.09.041","volume":"883\u2013884","author":"Adaway","year":"2012","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"key":"D3RA00310H\/cit21\/1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jpba.2018.12.040","volume":"166","author":"Avataneo","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"D3RA00310H\/cit22\/1","volume-title":"Q2(R1): validation of analytical procedure: text and methodology","author":"The International Conference on Harmonization (ICH)","year":"2005","unstructured":"The International Conference on Harmonization (ICH) , Q2(R1): validation of analytical procedure: text and methodology , ICH , Geneva , 2005"},{"issue":"8","key":"D3RA00310H\/cit23\/1","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"17","key":"D3RA00310H\/cit24\/1","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s40265-018-1013-4","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"issue":"11","key":"D3RA00310H\/cit25\/1","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/ajh.25228","volume":"93","author":"Flinn","year":"2018","journal-title":"Am. J. Hematol."},{"key":"D3RA00310H\/cit26\/1","doi-asserted-by":"crossref","first-page":"14250","DOI":"10.1038\/ncomms14250","volume":"8","author":"Blais","year":"2017","journal-title":"Nat. Commun."},{"key":"D3RA00310H\/cit27\/1","doi-asserted-by":"crossref","first-page":"e9881","DOI":"10.7717\/peerj.9881","volume":"8","author":"Almomen","year":"2020","journal-title":"PeerJ"}],"container-title":["RSC Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/pubs.rsc.org\/en\/content\/articlepdf\/2023\/RA\/D3RA00310H","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:26:18Z","timestamp":1782851178000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.rsc.org\/ra\/article\/13\/12\/7929-7938\/823177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,3,8]]}},"URL":"https:\/\/doi.org\/10.1039\/d3ra00310h","relation":{},"ISSN":["2046-2069"],"issn-type":[{"value":"2046-2069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}